





A**OS for all M1****B****OS for ICI+TKI group****C****OS for TKI group****D**

Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease and treatment flows. Overall survival (OS) for patients with synchronous and metachronous metastatic FH-deficient RCC in the overall systemic treatment setting (A), ICI+TKI treatment setting (B), and TKI monotherapy setting (C); (D) Sankey diagram showing systemic treatment flows in patients with metastatic FH-deficient RCC.